Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. News
  7. Summary
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Real-time Estimate Tradegate  -  03:04:50 2023-01-30 am EST
1.375 EUR   +2.61%
01/09Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
MT
2022Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd
CI
2022Biofrontera AG Establishes UK Subsidiary to Strengthen Its Sales Activities in the Country
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biofrontera Ag Continues to Adhere to Forecast for Fiscal Year 2022

11/23/2022 | 09:00am EST

Biofrontera AG continued to adhere to its forecast for fiscal year 2022. Thus, the Group expects sales of EUR 24 to 27 million and positive EBITDA in 2022, provided that the encouraging business performance of the first nine months will continue.


ę S&P Capital IQ 2022
All news about BIOFRONTERA AG
01/09Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
MT
2022Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd
CI
2022Biofrontera AG Establishes UK Subsidiary to Strengthen Its Sales Activities in the Coun..
CI
2022Biofrontera Ag Continues to Adhere to Forecast for Fiscal Year 2022
CI
2022Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
2022Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $4.3M, vs. Street Est of $4.3M
MT
2022Biofrontera Says It Has Agreed to Buy Biofrontera AG Options
MT
2022BIOFRONTERA AG : RIGHTS ISSUE: 1 new share @ 1 EUR for 8 existing shares
FA
2022Biofrontera Appoints Fred Leffler as CFO
MT
2022Biofrontera Adopts Shareholder Rights Plan
MT
More news
Financials
Sales 2022 27,0 M 29,3 M 29,3 M
Net income 2022 -42,1 M -45,7 M -45,7 M
Net Debt 2022 - - -
P/E ratio 2022 -2,27x
Yield 2022 -
Capitalization 76,0 M 82,5 M 82,5 M
Capi. / Sales 2022 2,81x
Capi. / Sales 2023 2,23x
Nbr of Employees 102
Free-Float 49,7%
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,34 €
Average target price 2,80 €
Spread / Average Target 109%
EPS Revisions
Managers and Directors
Maria del Pilar de la Huerta Martinez Chief Financial Officer
Wilhelm Konrad Zours Chairman-Supervisory Board
Heikki Lanckriet Member-Supervisory Board
Helge Lubenow Member-Supervisory Board
Karlheinz Schmelig Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA AG-12.13%83
CSL LIMITED2.41%101 009
SAMSUNG BIOLOGICS CO.,LTD.-1.46%46 755
BIOGEN INC.4.75%41 772
WUXI BIOLOGICS (CAYMAN) INC.18.55%38 289
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.19.07%24 667